James Koropatnick
Overview
Explore the profile of James Koropatnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alotaibi F, Min W, Koropatnick J
Front Immunol
. 2024 Mar;
15:1256766.
PMID: 38487537
CD5 is a member of the scavenger receptor cysteine-rich superfamily that is expressed on T cells and a subset of B cells (B1a) cell and can regulate the T cell...
2.
El-Hajjar M, Gerhardt L, Hong M, Krishnamoorthy M, Figueredo R, Zheng X, et al.
Mol Ther
. 2022 Sep;
31(2):535-551.
PMID: 36068918
Immune checkpoint blockade can induce potent and durable responses in patients with highly immunogenic mismatch repair-deficient tumors; however, these drugs are ineffective against immune-cold neuroblastoma tumors. To establish a role...
3.
Liu Q, Xiong J, Xu D, Hao N, Zhang Y, Sang Y, et al.
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008676
We have previously found that TdT-interacting factor 1 (TdIF1) is a potential oncogene expressed in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. However, its exact mechanism...
4.
Alotaibi F, Vincent M, Min W, Koropatnick J
Front Immunol
. 2021 Feb;
11:584937.
PMID: 33584650
CD5, a member of the scavenger receptor cysteine-rich superfamily, is a marker for T cells and a subset of B cells (B1a). CD5 associates with T-cell and B-cell receptors and...
5.
Gameiro S, Ghasemi F, Barrett J, Koropatnick J, Nichols A, Mymryk J, et al.
Methods Enzymol
. 2020 Mar;
636:49-76.
PMID: 32178827
The importance of the immune system in combating many different types of malignancies has been firmly established. Indeed, the success of immune checkpoint-blocking antibodies in cancer treatment has focused the...
6.
Zhang M, Shi Y, Zhang Y, Wang Y, Alotaibi F, Qiu L, et al.
Cancer Immunol Immunother
. 2020 Feb;
69(6):951-967.
PMID: 32076794
Dendritic cell (DC) based immunotherapy is a promising approach to clinical cancer treatment. miRNAs are a class of small non-coding RNA molecules that bind to RNAs to mediate multiple events...
7.
Alotaibi F, Rytelewski M, Figueredo R, Zareardalan R, Zhang M, Ferguson P, et al.
Eur J Immunol
. 2020 Jan;
50(5):695-704.
PMID: 31943150
CD5 is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signalling and impair CTL activation and is a therapeutic targetable tumour antigen expressed...
8.
Zhang M, Gao D, Shi Y, Wang Y, Joshi R, Yu Q, et al.
Open Biol
. 2019 Oct;
9(10):190061.
PMID: 31594465
Blockade of inhibitory receptors (IRs) is one of the most effective immunotherapeutic approaches to treat cancer. Dysfunction of miRNAs is a major cause of aberrant expression of IRs and contributes...
9.
Zhang Y, Wang Z, Huang Y, Ying M, Wang Y, Xiong J, et al.
Signal Transduct Target Ther
. 2018 Oct;
3:28.
PMID: 30345081
TdT-interacting factor 1 (TdIF1) is a ubiquitously expressed DNA- and protein-binding protein that directly binds to terminal deoxynucleotidyl transferase (TdT) polymerase. Little is known about the functional role of TdIF1...
10.
Gameiro S, Ghasemi F, Barrett J, Koropatnick J, Nichols A, Mymryk J, et al.
Oncoimmunology
. 2018 Oct;
7(10):e1498439.
PMID: 30288365
Cancers progress when the immune system fails to identify and eliminate malignant cells. Recognition of this, combined with advances in tumor immunology, has allowed development of therapies that induce effective...